- Home
- VCEL vs TGTX Comparison
VCEL vs TGTX Comparison
Compare VCEL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- TGTX
- Stock Information
- Founded
- VCEL 1989
- TGTX 1993
- Country
- VCEL United States
- TGTX United States
- Employees
- VCEL N/A
- TGTX N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- VCEL Health Care
- TGTX Health Care
- Exchange
- VCEL Nasdaq
- TGTX Nasdaq
- Market Cap
- VCEL 2.1B
- TGTX N/A
- IPO Year
- VCEL 1997
- TGTX 1995
- Fundamental
- Price
- VCEL $41.83
- TGTX $35.47
- Analyst Decision
- VCEL Strong Buy
- TGTX Strong Buy
- Analyst Count
- VCEL 8
- TGTX 5
- Target Price
- VCEL $62.00
- TGTX $40.80
- AVG Volume (30 Days)
- VCEL 430.3K
- TGTX 1.7M
- Earning Date
- VCEL 07-31-2025
- TGTX 08-05-2025
- Dividend Yield
- VCEL N/A
- TGTX N/A
- EPS Growth
- VCEL 521.85
- TGTX N/A
- EPS
- VCEL 0.05
- TGTX 0.24
- Revenue
- VCEL $238,541,000.00
- TGTX $386,386,000.00
- Revenue This Year
- VCEL $23.03
- TGTX $84.81
- Revenue Next Year
- VCEL $24.52
- TGTX $38.34
- P/E Ratio
- VCEL $805.02
- TGTX $149.16
- Revenue Growth
- VCEL 14.80
- TGTX 33.54
- 52 Week Low
- VCEL $37.39
- TGTX $16.65
- 52 Week High
- VCEL $63.00
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- VCEL 47.28
- TGTX 43.41
- Support Level
- VCEL $40.53
- TGTX $35.18
- Resistance Level
- VCEL $43.57
- TGTX $38.08
- Average True Range (ATR)
- VCEL 1.67
- TGTX 1.33
- MACD
- VCEL -0.10
- TGTX -0.10
- Stochastic Oscillator
- VCEL 27.68
- TGTX 23.97
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.